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Abstract 1 
Objectives: Peripheral arterial disease and intermittent claudication (PAD-IC) negatively 2 
affects physical activity and function. There is evidence for plantarflexor muscle dysfunction 3 
and weakness, however, the extent to which this dysfunction can be attributed to reduced 4 
muscle size and/or quality is not yet known. This study investigated whether in vivo 5 
plantarflexor muscle quality during static and dynamic contractions are altered by PAD-IC 6 
and whether such changes are associated with impaired walking endurance (according to 7 
initial and absolute claudication distances). Methods: A total of 22 participants were 8 
recruited, consisting of 10 healthy controls and 12 claudicants with occlusion of the 9 
superficial femoral artery (seven unilateral and five bilateral). Muscle quality of the 10 
combined gastrocnemius muscles during static contractions was calculated by normalising 11 
the estimated maximal potential muscle force to the physiological cross-sectional area of both 12 
lateral and medial gastrocnemius. Muscle quality during dynamic contractions of the 13 
combined plantarflexor muscles was calculated as the ratio of peak voluntary concentric 14 
plantarflexor power and the summed volume of lateral and medial gastrocnemius. Results: 15 
Dynamic muscle quality was 24% lower in both the claudicating-limb and asymptomatic-16 
limb groups compared to controls (P=.017 and P=.023). The differences were most apparent 17 
at the highest contraction velocity (180°/s). Dynamic muscle quality was associated with 18 
reduced walking endurance (R=.689, P=.006 and R=.550, P=.042 for initial and absolute 19 
claudication distance, respectively). The claudicating-limb group demonstrated a trend 20 
towards reduced static muscle quality compared to controls (22%, P=.084). The relative 21 
contribution of the soleus muscle to plantarflexion maximum voluntary contraction was 22 
significantly higher in both claudicating-limb and asymptomatic-limb groups compared to 23 
controls (P=.012 and P=.018). Conclusions: The muscle strength of the plantarflexors in 24 
those with PAD-IC appears to be impaired at high contraction velocities. This may be 25 
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explained by some reduction in gastrocnemii muscle quality and a greater reliance on the 1 
prominently type I fibred soleus muscle. The reduced dynamic capability of the plantarflexor 2 
muscles was associated with disease severity and walking ability, therefore efforts to improve 3 
plantarflexor power through dynamic exercise intervention are vital to maintain functional 4 
performance. 5 
 6 
  7 
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Introduction 1 
Peripheral arterial disease and intermittent claudication (PAD-IC) refers to a chronic lower-2 
limb atherosclerotic disease that primarily affects the older population
(1)
. The disease 3 
negatively impacts on functional ability
(2)
, physical activity levels
(3)
 and quality of life
(4)
. The 4 
most frequent site of claudication pain is in the plantarflexor (triceps surae) muscles
(5)
, where 5 
there are clear signs of dysfunction, such as reduced ankle power generation during gait
(6,7)
. 6 
However, the few previous studies directly investigating plantarflexor function are 7 
inconsistent about whether strength is diminished in claudicants compared to healthy 8 
controls
(8-10)
. Plantarflexor strength is a strong predictor of mortality in men with PAD-9 
IC
(11,12)
, so it is essential to understand the nature of any strength impairments and the 10 
underlying mechanisms, so that exercise interventions may be designed accordingly. 11 
 12 
The “strength” of a muscle group, as measured externally by hand-held or isokinetic 13 
dynamometer, depends on numerous factors, including: muscle size and quality; voluntary 14 
activation level; any resistance to intended effort from co-activation of the antagonist muscle; 15 
and length of the moment arm about which the muscle is working 
(13)
. Muscle quality during 16 
isometric contractions (often known as specific tension or specific force) is defined as the 17 
maximal potential muscle force (calculated using the above factors) normalised to the 18 
physiological cross-sectional area 
(13)
. In PAD-IC voluntary joint moments have been 19 
measured previously
(8-10)
 but the factors that determine externally-measured strength have 20 
not. Consequently, the underlying mechanisms explaining any disease-induced strength 21 
losses have not been identified, and muscle quality has not yet been quantified in claudicants. 22 
Thus, it remains unknown if/how any deleterious changes in muscle properties contribute to 23 
5 
 
reduced functional ability. Therefore, it is not apparent exactly how exercise interventions 1 
should be optimally designed to improve physical function.  2 
 3 
Muscle quality is known to reduce with ageing and disuse
(14)
 and increase in response to 4 
resistance training
(15)
. It is reasonable to assume muscle quality would be altered in 5 
claudicants given that the disease primarily affects the elderly
(1)
 and is associated with 6 
reduced physical activity
(3)
. Additional factors associated with PAD-IC that may further 7 
affect muscle quality include intra-muscular fat infiltration
(16)
, which would reduce the 8 
quantity of contractile material within a given muscle, and altered fibre type composition, 9 
with contradicting findings of shifts towards more type II (fast-twitch)
(17-19)
 and conversely to 10 
more type I fibres (slow-twitch)
(20,21)
. As specific tension differs between fibre types
(22)
 any 11 
changes at the fibre level may affect whole muscle quality, force producing potential and thus 12 
functional strength. If isometric muscle quality is altered with PAD-IC then it follows that the 13 
ability to utilise this force producing potential during dynamic contraction would also be 14 
impaired, especially if the proportion of fast type-II fibres is reduced. Any change in muscle 15 
quality might also reduce the responsiveness of muscles to exercise training, a vital 16 
component of treatment for PAD-IC
(5)
. This may contribute to the inconsistent effects 17 
reported following progressive resistance training in claudicants
(23)
.  18 
 19 
The purpose of the study was to determine whether PAD-IC causes changes in the strength 20 
characteristics of the plantarflexors and quality of the gastrocnemii muscles. This was 21 
achieved by exploring relationships between static and dynamic measures of muscle quality 22 
and disease severity (as assessed through the ankle brachial pressure index; ABPI), and 23 
comparing asymptomatic and symptomatic limbs of claudicants to those of healthy controls. 24 
6 
 
To explore the effects of muscle quality on function, correlations were performed between 1 
the factors affecting muscle strength and walking endurance (quantified through initial and 2 
absolute claudication distances). Our first hypothesis was that increased disease severity 3 
would be associated with lower voluntary isometric plantarflexion moments and concentric 4 
plantarflexion powers, and that this would be explained by smaller muscle size and reduced 5 
static and dynamic muscle quality. Our second hypothesis was that walking endurance would 6 
be associated with reduced maximum isometric plantarflexion moment, concentric 7 
plantarflexion power, and static and dynamic muscle quality. 8 
 9 
Methods 10 
Participants 11 
Ethical approval was granted by the National Health Service Research Ethics Committee 12 
(REC reference: 11/YH/0335). A total of 22 participants were recruited consisting of 12 13 
claudicants (seven unilateral, five bilateral) and ten healthy controls (Table I). Claudicants 14 
were recruited via consultant referral from a local outpatient vascular clinic. Male and female 15 
participants aged between 55-80 years who were diagnosed with Rutherford Grade 1 Chronic 16 
Limb Ischemia
(24)
 with an arterial narrowing of the superficial femoral artery were considered 17 
for inclusion. Those with extensive disease were also included, however the primary stenosis 18 
identified using vascular imaging was located in the superficial femoral artery for all 19 
participants. Healthy controls were recruited from the local community via email and word of 20 
mouth. Individuals deemed to have severe or acute cardiovascular, musculoskeletal or 21 
pulmonary illness were excluded along with those with a previous lower-limb joint 22 
replacement. Any individuals with a history of neurological disorders, stroke, myocardial 23 
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infarction or life-limiting diseases, such as cancer, were also excluded. All participants gave 1 
written informed consent prior to testing 2 
 3 
Disease severity 4 
Disease severity was determined using the ankle brachial pressure index/ratio (ABPI). 5 
Systolic blood pressure was measured in the posterior tibial and dorsalis pedis arteries of each 6 
leg and the brachial pressure of both arms, separately, using a sphygmomanometer cuff and a 7 
hand held Doppler instrument (Parks Medical Electronics Inc, Oregon, USA). ABPI 8 
measures for both lower limbs were taken pre- and post- a standardised exercise protocol 9 
performed on a motorised treadmill (5minutes at 2.5km/h at 10% incline)
(5)
. Those unable to 10 
complete 5 minutes were able to stop at the point of maximum claudication pain. In 11 
accordance with standard protocol, the ABPI for both legs was then calculated as the higher 12 
of the two leg artery pressures normalised to the higher brachial pressure of the two arms
(5)
. 13 
The post-exercise ABPI was subsequently used to categorise the limbs of the participants as 14 
well as classify disease severity. Any limb with an ABPI <0.9 was classified as claudicating 15 
and represents the ‘claudicating-limb’ group. The asymptomatic limb of the unilateral 16 
claudicants was identified (ABPI ≥0.9) and represents the ‘asymptomatic-limb’ group. 17 
Control participants also undertook the exercise protocol to determine ABPI values, 18 
confirming the absence of PAD-IC. 19 
 20 
Walking endurance 21 
The 6-minute walk test was modified to be performed on level ground and combined with a 22 
pain rating based on the ACSM claudication pain scale
(25)
. This method is a reliable 23 
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alternative to treadmill walk tests
(26)
 and allows participants to walk for longer than 6-minutes 1 
if they are able. Patients walked continuously along a 10m walkway at a self-selected pace 2 
and informed the investigator of the level of pain and position on the pain scale every 20m. 3 
Initial claudication distance was classed as level 1 on the pain scale and signified the onset of 4 
pain. Absolute claudication distance was classed as level 4 on the pain scale, represented 5 
maximal pain and signified the end of the test. 6 
 7 
Experimental protocol 8 
The static muscle quality (specific tension) of the combined gastrocnemii muscles was 9 
defined as maximal potential Achilles tendon force (equation 1) normalised to the reduced 10 
gastrocnemii physiological cross-sectional area (equation 2)
(2)
;  11 
1) Maximal Achilles tendon force =
(Joint MVC + Antagonist moment - Soleus moment)*100
(Moment arm * Voluntary activation)
 12 
2) Reduced gastrocnemii PCSA= (
GL V
GL FLMVC
) *cos·GLθMVC+ (
GM V
GM FLMVC
) * cos·GMθMVC 13 
where PCSA is physiological cross-sectional area, GL is lateral gastrocnemius, GM is medial 14 
gastrocnemius, V is muscle volume, FL is fascicle length and θ is pennation, both quantified 15 
during maximum voluntary contraction (MVC). 16 
The methods used to determine each component of these equations are detailed below. 17 
 18 
Measurements and calculations for maximal Achilles tendon force 19 
Joint moment 20 
9 
 
Participants were secured into the chair of an isokinetic dynamometer (Biodex System 3, 1 
Biodex Medical Systems Inc, New York, USA), sat in an upright position with their hip 2 
flexed (85°), knee extended (0°) and the lateral malleolus aligned with the centre of rotation 3 
of the dynamometer arm during muscle contraction. To ensure isometric muscle strength of 4 
the gastrocnemii muscles was measured at the optimum joint angle, MVCs were elicited at 5 
10° intervals from maximum plantarflexion to maximum dorsiflexion. Verbal encouragement 6 
was given throughout all trials. Three maximal isometric plantarflexion contractions were 7 
performed at each joint angle and the peak gravity corrected joint moment was taken forward 8 
for further analysis. For all participants, peak joint moment was achieved at maximum 9 
dorsiflexion, which was consistent with healthy populations
(28)
. All further trials to establish 10 
voluntary and antagonist activation, soleus contribution, fascicle length and pennation were 11 
performed in this joint position.  12 
 13 
Antagonist co-activation 14 
The contribution of antagonist muscle activity to the measured joint moment was estimated 15 
from the surface electromyography (EMG) (Telemyo 2400T, Noraxon, Arizona, USA) of the 16 
tibialis anterior, to represent the ankle dorsiflexors. Electrode placement and skin preparation 17 
were according to standardised guidelines
(29)
. The EMG of the tibialis anterior was recorded 18 
at 2000Hz synchronously with joint moments during the isometric plantarflexion contractions 19 
(working as an antagonist) and then combined with the EMG-moment relationship during 20 
dorsiflexion contractions (working as an agonist) to estimate the antagonist co-activation 21 
moment
(27)
. 22 
 23 
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Soleus contribution 1 
The contribution of soleus to plantarflexion moment was quantified with additional 2 
plantarflexion contractions with the knee flexed where gastrocnemii muscle does not 3 
contribute to the measured joint moment
(28)
. Activation changes between the two positions 4 
were corrected using the EMG-moment relationship in two joint configurations using 5 
equation 3; 6 
3) Soleus moment Knee 0°=
Soleus moment Knee 90°* Soleus EMG Knee 0°
Soleus EMG Knee 90°
 7 
 8 
Activation capacity 9 
The level of muscle activation achieved during voluntary contraction was calculated using the 10 
interpolated twitch technique
(30)
. Percutaneous neuromuscular electrical stimulation (200 µs 11 
pulse duration, 400 V; Digitimer model DS7AH, Welwyn Garden City, UK) was used to 12 
evoke involuntary twitches of the plantarflexor muscles. Maximal current intensity was 13 
determined by progressively stimulating the calf with electrical twitches of increasing current 14 
steps of 50 mA until further increments in current did not increase joint torque. Once this 15 
level was established, a superimposed twitch was evoked at the point of isometric MVC and a 16 
resting twitch was applied approximately 3 s afterwards. This was repeated during three trials 17 
at peak joint angle. The percentage of voluntary activation was calculated using equation 18 
4
(31)
: 19 
4) Voluntary activation= (1-
Superimposed twitch
Resting twitch
) x 100 20 
 21 
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Measurement of moment arm length 1 
Achilles tendon moment arm length was calculated using the tendon travel method
(32)
 and 2 
using ultrasound imaging (50-mm probe length, MyLab50 x-vision, Esaote Biomedica, 3 
Genoa, Italy) to quantify linear myotendinous junction displacement.  4 
 5 
Measures of muscle size at rest and architecture during MVC 6 
Participants were asked to lie prone on a plinth with their ankle plantarflexed and supported 7 
on the bed with the musculature relaxed. To quantify lateral and medial gastrocnemius 8 
muscle volume, serial transverse ultrasound images of each muscle were overlaid to 9 
reconstruct a full anatomical cross-sectional area at 25, 50 and 75 % of muscle length. 10 
Muscle volume was then calculated using the anatomical cross-sectional area’s and muscle 11 
length by considering each muscle as two cones at either end of two truncated cones which is 12 
a reliable and valid alternative to MRI imaging
(15)
. Lateral and medial gastrocnemius volume 13 
were combined for total gastrocnemii muscle volume.  14 
 15 
Optimum fascicle length and pennation angle during MVC were measured from synchronised 16 
sagittal-plane ultrasound video-recordings of the muscle belly of lateral and medial 17 
gastrocnemius , captured at 25Hz. The frame corresponding to peak tendon force was 18 
extracted for each muscle during three separate MVC trials and analysed in ImageJ (version 19 
1.44, NIH, USA)
(27)
. 20 
 21 
Measures of dynamic muscle quality 22 
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Isokinetic plantarflexion joint power was measured across the participants’ full range of 1 
motion at angular velocities of 60, 90, 120 and 180 °/s in the same dynamometer set up 2 
described above. These velocities were selected to represent the range of joint speeds 3 
experienced during gait
(33)
. Five concentric contractions were performed at each velocity. 4 
Peak power from each trial was recorded and the power-velocity profile constructed. The 5 
volume-normalised power-velocity relationship was established by normalising power at 6 
each velocity to gastrocnemii muscle volume, since the relative size of the gastrocnemii 7 
muscles and the soleus remain constant with ageing
(34)
. Dynamic muscle quality was defined 8 
as peak power normalised to gastrocnemii muscle volume. Adequate rest (>1 min) was 9 
provided between trials. 10 
 11 
Statistical analysis 12 
A linear relationship exists between advancing age and dynamic muscle quality
(35)
 therefore a 13 
Pearson’s partial product-moment correlation was performed to control for the influence of 14 
age and assess relationships between disease severity (as assessed by ABPI), walking 15 
endurance (as assessed by initial and absolute claudication distance) and gastrocnemii 16 
physiological cross-sectional area, volume and measures pertaining to static and dynamic 17 
muscle quality. 18 
 19 
A one-way ANOVA was conducted to determine if significant between differences existed 20 
between the claudicating-limb and asymptomatic-limb groups and healthy controls. Data 21 
were assessed for normality,using Shapiro-Wilk’s test for normality, and for outliers through 22 
13 
 
box plot analysis. Sidak post-hoc was applied when appropriate. Mann-Whitney U tests were 1 
performed for non-parametric measures. 2 
 3 
For all statistical tests, significance was accepted at P≤.05 and trends were accepted at P<.10. 4 
For correlation and regression analyses, a moderate relationship was accepted as R=.40–.59, a 5 
strong relationship was accepted as R=.60–.79 and a very strong relationship was accepted as 6 
R=.80–1(36). Since low ABPI values indicate high disease severity a positive relationship 7 
indicates a decrease in the respective parameter with worsening disease. 8 
 9 
Results 10 
No significant differences were found between groups in height (P=.230) or mass (P=.167) 11 
(Table I). Whilst age and gender were not exactly matched between groups, the between 12 
group age-difference (~5years) was not statistically significant and likely too small to have 13 
influenced our results
(35)
 and there is no reason to believe gender differences influenced our 14 
measures of muscle quality
(27)
. Between-group differences in ABPI were consistent with 15 
disease presentation. One participant (unilateral claudicant) had type II diabetes that was 16 
being managed by diet intervention only. Inspection of this data, in comparison to the full 17 
claudicant cohort, revealed adaptations that were in keeping with those with similar ABPI 18 
values and of similar ages. We do not believe that, for this individual participant, diabetes 19 
was a confounding factor.  20 
 21 
 22 
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Table I. Participant characteristics. Data are presented as group mean (SD) unless otherwise 1 
stated. BMI – Body mass index, ABPI – Ankle brachial pressure index. 2 
 3 
  4 
 
Claudicating-
limb 
Asymptomatic-
limb 
Healthy 
control 
# 12 7 10 
40 
61.6 (3.6) 
1.66 (0.09) 
72.3 (10.9) 
26.1 (3.7) 
% Males 75 57 
Age (years) 65.0 (6.7) 66.1 (7.5) 
Height (m) 1.71 (0.08) 1.69 (0.10) 
Mass (Kg) 81.5 (18.2) 82.3 (21.1) 
BMI (Kg/m
2
) 27.7 (5.1) 28.5 (4.8) 
ABPI pre-exercise 
ABPI post-exercise 
0.81 (0.23)
 
1.01 (0.16) 0.99 (0.10)
 
0.55 (0.21)
 
0.90 (0.06) 1.00 (0.13)
 
Initial claudication distance (m) 105 (45) N/A N/A 
Absolute claudication distance (m) 265 (136) N/A N/A 
% Hypertension 50 43 10 
% Hypercholesterolemia 58 71 20 
% past smokers 58 57 30 
% present smokers 42 43 0 
15 
 
Correlations 1 
Increased disease severity was not associated with any change in isometric MVC joint 2 
moment or static muscle quality, but was significantly correlated with reduced power at 3 
120°/s and reduced power/volume at 120°/s and 180°/s, the latter being defined as 4 
significantly reduced dynamic muscle quality (all R and p values are presented in Tables II, 5 
and III). A trend was observed for smaller gastrocnemii physiological cross-sectional area 6 
with higher disease severity (P=.073) (Table II). 7 
 8 
Shorter initial and absolute claudication distance were associated with larger gastrocnemii 9 
muscle volume, lower activation capacity and reduced dynamic muscle quality. Shorter 10 
absolute claudication distance was also correlated with reduced static muscle quality and 11 
shorter moment arm lengths (all R and p values are presented in Tables II and III). Trends 12 
towards an association existed between shorter absolute claudication distance and reduced 13 
tendon force (P=.053) (Table II). 14 
 15 
  16 
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Table II. Pearson correlations (controlled for the influence of age) between disease severity (ABPI), walking endurance (ICD and ACD) and 1 
gastrocnemii size and measures of static muscle quality. PCSA – physiological cross-sectional area. Dark shaded values represent those reaching 2 
significance (P≤.05) and light shaded values represent those demonstrating trends towards significance (P<.10). 3 
 
 MVC 
Soleus 
contribution 
Activation 
capacity 
Moment arm Tendon force 
ABPI Correlation .055 -.048 -.312 -.377 .198 
 Significance .847 .865 .258 .165 .480 
ICD Correlation -.161 -.419 .589 -.424 .091 
 Significance .566 .120 .021 .116 .747 
ACD Correlation .188 -.277 .514 -.668 .508 
 Significance .502 .318 .050 .007 .053 
  
Gastrocnemii 
volume 
Gastrocnemii 
reduced 
PCSA 
Static muscle 
quality 
  
ABPI Correlation -.368 .475 -.009   
 Significance .117 .073 .976   
ICD Correlation -.858 -.386 .353   
 Significance .000 .156 .257   
ACD Correlation -.851 -.079 .632   
 Significance .029 .779 .011   
 4 
 5 
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Table III. Pearson correlations (controlled for the influence of age) between disease severity (ABPI), walking endurance (ICD and ACD) and 1 
measures of dynamic muscle quality. Dark shaded values represent those reaching significance (P≤.05). 2 
 Power 60°/s 90°/s 120°/s 180°/s 
ABPI Correlation .071 .375 .674 .375 
 Significance .803 .398 .012 .168 
ICD Correlation -.256 -.277 -.123 -.368 
 Significance .357 .318 .688 .177 
ACD Correlation -.007 -148 .064 -.262 
 Significance .981 .598 .836 .346 
 Power/Volume 60°/s 90°/s 120°/s 180°/s 
ABPI Correlation .174 .323 .716 .541 
 Significance .600 .240 .006 .037 
ICD Correlation .418 .364 .408 .689 
 Significance .121 .182 .166 .006 
ACD Correlation .421 .263 .372 .550 
 Significance .118 .344 .211 .042 
 3 
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Between group comparisons 1 
There were no differences between groups in isometric joint MVC, however the soleus 2 
contribution to this joint moment was significantly greater in both the claudicating-limb and 3 
asymptomatic-limb groups than in healthy controls (P=.008 and P=.012, respectively). The 4 
claudicating-limb group demonstrated trends towards reduced static muscle quality compared 5 
to healthy controls (P=.084) (Table IV).  6 
 7 
At 120°/s the asymptomatic-limb group demonstrated trends towards reduced power (P=.071) 8 
with similar trends observed at 180°/s in the claudicating-limb group compared to healthy 9 
controls (P=.100). When normalised to gastrocnemii muscle volume, the asymptomatic-limb 10 
group had significantly reduced power/volume at 120°/s (P=.036) compared to healthy 11 
controls and both the asymptomatic-limb (P=.023) and claudicating-limb (P=.017) groups 12 
had significantly reduced power/volume at 180°/s (dynamic muscle quality) (Figure 1).  13 
 14 
  15 
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Table IV. Group mean (SD) measures of static muscle quality. Dark shaded values represent 1 
those reaching significance (P≤.05) and light shaded values represent those demonstrating 2 
trends towards significance (P<.10).  PCSA – physiological cross-sectional area. 3 
 
Claudicating-
limb 
Asymptomatic-
limb 
Healthy control 
MVC (Nm) 120.6 (32.5) 121.7 (36.1) 127.5 (34.3) 
Antagonist co-activation (%) 2.74 (2.2) 2.35 (2.5) 2.01 (1.85) 
Plantarflexor moment (Nm) 123.4 (31.8) 124.0 (35.4) 130.0 (36.9) 
Soleus contribution (%) 62.7 (6.3)
Co
 62.1 (1.4)
Co
 55.6 (7.9) 
Gastronemii moment (Nm) 45.1 (10.3) 46.9 (13.3) 58.1 (20.2) 
Activation capacity (%) 90.7 (6.5) 87.9 (7.8) 90.4 (4.6) 
Gastrocnemii moment at 100% (Nm) 49.6 (10.7) 53.5 (15.5) 64.7 (24.4) 
Moment arm (cm) 3.44 (0.58) 3.71 (0.76) 3.24 (0.58) 
Tendon force (N) 1500.2 (471.8) 1506.9 (431.2) 2001.7 (722.7) 
Muscle size and static quality    
Gastrocnemii volume (cm
3
) 267.4 (71.5) 249.8 (51.1) 243.1 (71.3) 
Gastrocnemii reduced PCSA (cm
2
) 55.4 (9.8) 54.0 (14.1) 58.1 (12.0) 
Static muscle quality (N/cm
2
) 27.1 (6.6)
Co
 28.8 (8.3) 34.5 (10.4) 
Cl = vs Claudicating-limb group, A = vs Asymptomatic-limb group Co = vs Healthy control 4 
group  5 
  6 
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Figure 1. Group mean power-velocity (a) and normalised power-velocity (b) profiles for 
claudicating-limb (▲), asymptomatic-limb (∆) and healthy controls (□). Dark shaded 
values represent those reaching significance (P≤.05) and light shaded values represent 
those demonstrating trends towards significance (P<.10). Cl = vs Claudicating-limb group, 
A = vs Asymptomatic-limb group Co = vs Healthy control group.  
  1 
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Discussion 1 
The aim of the study was to investigate the effects of peripheral arterial disease and 2 
intermittent claudication (PAD-IC) on the strength, power, size and in vivo whole muscle 3 
quality of the plantarflexors. We found no effects of disease on external measures of 4 
“strength” during static or low speed contractions, but the claudicants relied on the 5 
predominantly type I-fibred soleus to develop overall strength more than healthy controls. 6 
Significant strength differences between claudicants and controls were apparent during higher 7 
speed (≥120°/s) contractions. These data support our hypotheses that the dynamic muscle 8 
quality of claudicants was reduced compared to healthy controls, and this was associated with 9 
poorer walking endurance. These novel findings suggest that impaired muscle quality and a 10 
greater reliance on the soleus muscle contribute to reduced dynamic strength of claudicants at 11 
high speeds, which in turn contributes to the impaired functional ability seen in this 12 
population. 13 
 14 
Previous studies investigating plantarflexor strength in individuals with PAD-IC are 15 
inconsistent
(8-10)
 and comparisons between studies are confounded by differing methods of 16 
strength assessment. This study quantified plantarflexor strength across a range of contraction 17 
speeds, and observed no between-group differences at low velocities. However, the power 18 
generating capacity of the claudicants was 13-26% lower than controls at speeds of 120-19 
180°/s. Interestingly, this was the case for both claudicating-limb and asymptomatic-limb 20 
groups. This indicates either the presence of systemic effects of ischemia in the 21 
‘asymptomatic’-limb or that deleterious adaptations were driven by the relative inactivity 22 
caused by the symptomatic limb. Isometric plantarflexor strength has previously been 23 
reported as a strong predictor of mortality in men with PAD-IC
(11,12)
; however the current 24 
22 
 
data suggest that dynamic contractions at higher velocities may be more sensitive to 1 
functional deteriorations, which was not apparent in previous sub-group analyses
(37)
. Future 2 
functional assessments and measures of plantarflexor strength should consider the use of 3 
dynamic, concentric tests in order to detect strength losses early in diagnosis and to identify 4 
those with greater strength impairments. 5 
 6 
Whilst voluntary joint moments and powers are simple and time-efficient measures, they do 7 
not provide information regarding the underlying mechanisms contributing to the externally 8 
measured strength. Despite minimal between-group differences in isometric MVC, a 9 
substantially lower (25%, but non-significant) tendon force was found in both claudicating-10 
limb and asymptomatic-limb groups compared to controls. Combined with similar 11 
physiological cross-sectional areas, this led to a trend towards reduced static muscle quality 12 
(21%) in the claudicating-limb group, and a non-significant reduction of 16% in the 13 
asymptomatic-limb group, compared to controls. These effects were not mirrored in the 14 
correlations with ABPI, suggesting other stimuli must exist, such a physical activity levels, to 15 
drive these reductions in static gastrocnemii muscle quality of claudicants.  16 
 17 
The reduced tendon force in the claudicating-limb group, despite similar joint moments 18 
between groups, can be attributed to a greater (12%) contribution of the soleus to the overall 19 
joint moment, compared to healthy controls. This increased reliance on the soleus during 20 
plantarflexion contractions may be linked to the proposed shift in fibre type in claudicants
(17-21 
21)
. Therefore, the increased contribution from the slower, type I-dominant soleus muscle
(38)
 22 
may act as a means to reduce the metabolic cost of the task. However, during dynamic 23 
23 
 
contractions, a greater contribution from soleus would have a detrimental effect on the ability 1 
to generate power, particularly at high speeds, which is consistent with the present data.   2 
 3 
When muscle power was normalised to volume (dynamic muscle quality) between-group 4 
differences became larger and significant associations with walking endurance and disease 5 
severity were apparent. This corroborates previous reports of reduced ankle plantarflexor 6 
power per kg body mass in gait
(6,7)
 and demonstrates the importance of plantarflexor power 7 
for functional performance. The reductions in dynamic muscle quality were associated with 8 
changes in walking performance that have previously been reported as clinically meaningful 9 
(>50m)
(39)
. Long-term efforts to monitor the implications of this appear warranted, and 10 
quantification of dynamic muscle quality may provide a useful outcome measure in these 11 
efforts. Exercise prescription is a primary treatment option in PAD-IC to improve mobility 12 
and to combat muscle weakness
(5)
. It appears that such training interventions should target 13 
improvements in plantarflexor power by redressing the relative contribution from the soleus 14 
and gastrocnemii muscles through dynamic exercise programmes (high-velocity resistance 15 
training). Future work should endeavour to assess how these important musculoskeletal 16 
parameters respond to (exercise-based) interventions and whether they lead to the predicted 17 
improvements in walking capacity. 18 
 19 
Correlation analysis revealed that variations in activation capacity amongst the claudicating-20 
limb group significantly affected walking endurance. This would increase the perceived effort 21 
of walking, possibly leading to altered gait mechanics to redistribute joint kinetics, and 22 
consequently alter movement efficiency and endurance. Activation level was not quantified 23 
during the isokinetic trials because muscle stimulation during dynamic contractions is 24 
24 
 
technically very challenging, particularly for the plantarflexors where the muscle group 1 
works almost exclusively on the ascending limb of the force-length relationship, so 2 
stimulation at optimal muscle length is not possible. Future work should endeavour to 3 
investigate the activation capacity of the plantarflexor muscles during dynamic contractions, 4 
since it may be different to that in isometric conditions and could contribute to the specific 5 
power deficits at high velocities. This would provide greater understanding of the 6 
neuromuscular adaptations caused by PAD-IC and their influence on functional performance. 7 
 8 
Some limitations to the present study must be acknowledged. It is recognised that the present 9 
sample is small with a wide range of disease severity. Nonetheless we were able to detect 10 
between-group differences and meaningful associations with walking endurance, as such we 11 
consider this sample adequate to confirm the hypotheses. Static muscle quality should be 12 
calculated with measures of truly optimal muscle force and length, i.e., plateau of the force-13 
length relationship. As is typical for the plantarflexors, this plateau was not observed
(28)
 and 14 
we do not know whether participants reached optimal fascicle length. However, previous 15 
work has shown that small changes in joint position do not significantly affect estimates of 16 
muscle quality
(27)
. By calculating the quality of the entire gastrocnemii muscle group, errors 17 
associated with distributing tendon force between the lateral and medial gastrocnemii 18 
muscles were avoided. However, it was necessary to assume that once soleus contribution 19 
was removed, the Achilles’ tendon force reflected only that produced by the gastrocnemii 20 
muscle. Dynamic muscle quality was calculated as plantarflexor joint power normalised to 21 
gastrocnemii muscle volume only, assuming the relative size of these muscles remains 22 
constant, as is the case in ageing
(34)
. Claudicants relied on the soleus more than healthy 23 
controls did, meaning any error associated with this assumption will most likely 24 
underestimate the true between-group difference in dynamic muscle quality. Additionally, 25 
25 
 
moment arm length was determined during passive joint rotations at rest
(32)
 and it is known to 1 
change during contraction
(40)
. However, there is no reason to assume the change from rest to 2 
contraction would be different between controls and claudicants; consequently, we consider 3 
the comparisons presented in this study to remain valid. 4 
 5 
Conclusions 6 
The present study quantified the intrinsic quality of in vivo claudicant muscle for the first 7 
time. Dynamic plantarflexion strength, particularly at the highest velocity, was lower in 8 
claudicants compared to healthy controls and was significantly associated with disease 9 
severity and impaired walking endurance. When dynamic strength was normalised to muscle 10 
size (to calculate muscle quality) between group differences were larger and relationships 11 
with walking endurance were stronger. The impaired function at high velocities may be 12 
related to a reduction in maximal (static) muscle quality and an increased reliance on the 13 
predominantly type-I fibred soleus muscle. Efforts to monitor strength at high velocities 14 
appear the most appropriate way to detect functional losses early, and improving the dynamic 15 
capabilities of the plantarflexors is likely to help maintain walking endurance in claudicants.  16 
26 
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